Open AccessEruptive Keratoacanthomas Associated With Pembrolizumab Therapy
Author(s) -
Azael FreitesMartínez,
Bernice Y. Kwong,
Kerri E. Rieger,
Daniel G. Coit,
A. Dimitrios Colevas,
Mario E. Lacouture
Publication year - 2017
Publication title -
jama dermatology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.128
H-Index - 166
eISSN - 2168-6084
pISSN - 2168-6068
DOI - 10.1001/jamadermatol.2017.0989
Subject(s) - medicine , pembrolizumab , dermatology , keratoacanthoma , pathology , immunotherapy , cancer , basal cell
To our knowledge, there have been no previous reports of eruptive keratoacanthomas (KAs) in patients receiving pembrolizumab.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom